Structure Therapeutics Inc. GPCR
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors ("GPCRs"). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $225.3M | $108.8M | $70.1M | $36.2M | — |
| SG&A | $61.6M | $49.4M | $32.7M | $16.4M | — |
| Total operating expenses | $176.6M | $158.2M | $102.8M | $52.6M | — |
| Operating income | -$176.6M | -$158.2M | -$102.8M | -$52.6M | — |
| Pre-tax income | -$140.7M | -$122.2M | -$89.4M | -$51.3M | — |
| Income tax | $515.0K | $310.0K | $236.0K | $17.0K | — |
| Net income | -$141.2M | -$122.5M | -$89.6M | -$51.3M | — |
| EPS, basic | -0.80 | -0.78 | -0.81 | -5.51 | — |
| EPS, diluted | -0.80 | -0.78 | -0.81 | -5.51 | — |
| Shares, diluted (wtd. avg.) | $177.6M | $157.9M | $110.2M | $9.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $799.6M | $169.5M | $129.8M | $26.1M | $105.3M |
| Short-term investments | $646.6M | $714.0M | $337.5M | $64.8M | — |
| Total current assets | $1.57B | $891.2M | $473.6M | $93.1M | — |
| Property, plant and equipment | $6.7M | $3.5M | $3.2M | $1.0M | — |
| Total assets | $1.58B | $903.3M | $482.0M | $97.8M | — |
| Accounts payable | $13.9M | $8.0M | $4.7M | $6.0M | — |
| Total current liabilities | $63.3M | $36.0M | $24.7M | $13.0M | — |
| Total liabilities | $67.5M | $38.5M | $29.1M | $13.0M | — |
| Retained earnings | -$470.3M | -$329.1M | -$206.6M | -$117.0M | — |
| Total equity | $1.52B | $864.8M | $453.0M | -$115.1M | -$64.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M | -$46.1M | — |
| Depreciation and amortisation | $1.3M | $992.0K | $295.0K | $277.0K | — |
| Stock-based compensation | $29.0M | $18.8M | $8.2M | $2.5M | — |
| Capital expenditure | $3.6M | $1.3M | $2.2M | $155.0K | — |
| Investing cash flow | $89.8M | -$358.9M | -$268.3M | -$62.1M | — |
| Financing cash flow | $762.5M | $515.3M | $451.5M | $29.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047740.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |